A Study Assessing Molecular And Clinical Effect Of Nivolumab Or Pembrolizumab In Patients With Gynaecologic Malignancies
Latest Information Update: 10 Apr 2017
At a glance
- Drugs Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cervical cancer; Endometrial cancer; Fallopian tube cancer; Gynaecological cancer; Ovarian cancer; Peritoneal cancer; Squamous cell cancer
- Focus Pharmacodynamics; Pharmacogenomic; Therapeutic Use
- 10 Apr 2017 New trial record
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research.